Home
Scholarly Works
Complications of intravitreal injections: 2022
Journal article

Complications of intravitreal injections: 2022

Abstract

PURPOSE OF REVIEW: This review highlights the complications of both intravitreal injection procedure as well as different intravitreal medications including antivascular endothelial growth factors, antibiotics, antivirals, antifungals, methotrexate, and steroids. Techniques for reducing rates of endophthalmitis will also be discussed. RECENT FINDINGS: Intravitreal vancomycin can cause hemorrhagic occlusive retinal vasculitis resulting in severe vision loss. Intravitreal brolucizumab is associated with intraocular inflammation and retinal vasculitis resulting in significant vision loss. Face mask use by both patient and physician is not associated with increased risk of endophthalmitis and may decrease culture positive endophthalmitis. SUMMARY: Intravitreal injections continue to be one of the most commonly performed procedures by ophthalmologists. Although the injections are generally well tolerated, sight-threatening complications can occur including endophthalmitis, retinal detachment, and/or retinal vasculitis. Adverse events associated with specific medications are outlined below. Several safety measures have been shown to reduce rates of endophthalmitis, the most concerning complication of this procedure.

Authors

Patel D; Patel SN; Chaudhary V; Garg SJ

Journal

Current Opinion in Ophthalmology, Vol. 33, No. 3, pp. 137–146

Publisher

Wolters Kluwer

Publication Date

May 1, 2022

DOI

10.1097/icu.0000000000000850

ISSN

1040-8738

Contact the Experts team